NOD-Like Receptor Protein 3 Inflammasome Priming and Activation in Barrett's Epithelial Cells

Cellular and Molecular Gastroenterology and Hepatology

Volumn 2, Issue 4, 2016, Pages 439-453

  Nadatani, Yuji ^a,b   Huo, Xiaofang ^a   Zhang, Xi ^a   Yu, Chunhua ^a   Cheng, Edaire ^a   Zhang, Qiuyang ^a   Dunbar, Kerry B ^a   Theiss, Arianne ^d   Pham, Thai H ^a   Wang, David H ^a,c   Watanabe, Toshio ^b   Fujiwara, Yasuhiro ^b   Arakawa, Tetsuo ^b   Spechler, Stuart J ^a,c   Souza, Rhonda F ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d BAYLOR RESEARCH INSTITUTE   (United States)

Author keywords

Cytokine; Esophageal squamous cell; GERD; IL1 ; Pyroptosis

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 8; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; [2 (2,2,6,6 TETRAMETHYLPIPERIDIN 1 OXYL 4YLAMINO) 2 OXOETHYL]TRIPHENYLPHOSPHONIUM CHLORIDE;

ARTICLE; CELL ACTIVATION; CELL CULTURE; CYTOKINE RELEASE; ENZYME ACTIVITY; ENZYME RELEASE; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIMARY CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYROPTOSIS; SIGNAL TRANSDUCTION; SQUAMOUS CELL;

EID: 84975311521     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2016.03.006     Document Type: Article

References (41)

1. Spechler S.J., Souza R.F. Barrett's esophagus. N Engl J Med 2014, 371:836-845.
2. Spechler S.J. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 2013, 310:627-636.
3. Thrift A.P., Pandeya N., Whiteman D.C. Current status and future perspectives on the etiology of esophageal adenocarcinoma. Front Oncol 2012, 2:11.
4. Fitzgerald R.C., Abdalla S., Onwuegbusi B.A., et al. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 2002, 51:316-322.
5. Quante M., Bhagat G., Abrams J.A., et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 2012, 21:36-51.
6. Huo X., Zhang X., Yu C., et al. In oesophageal squamous cells exposed to acidic bile salt medium, omeprazole inhibits IL-8 expression through effects on nuclear factor-kappaB and activator protein-1. Gut 2014, 63:1042-1052.
7. Sollberger G., Strittmatter G.E., Garstkiewicz M., et al. Caspase-1: the inflammasome and beyond. Innate Immun 2014, 20:115-125.
8. Martinon F., Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 2004, 117:561-574.
9. Martinon F., Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 2007, 14:10-22.
10. Bergsbaken T., Fink S.L., Cookson B.T. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 2009, 7:99-109.
11. Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002, 10:417-426.
12. Guo H., Callaway J.B., Ting J.P. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 2015, 21:677-687.
13. Kolb R., Liu G.H., Janowski A.M., et al. Inflammasomes in cancer: a double-edged sword. Protein Cell 2014, 5:12-20.
14. Stowe I., Lee B., Kayagaki N. Caspase-11: arming the guards against bacterial infection. Immunol Rev 2015, 265:75-84.
15. Kayagaki N., Wong M.T., Stowe I.B., et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 2013, 341:1246-1249.
16. Oblak A., Jerala R. Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol 2011, 2011:609579.
17. Fukata M., Chen A., Vamadevan A.S., et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007, 133:1869-1881.
18. Gribar S.C., Anand R.J., Sodhi C.P., et al. The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation. J Leukoc Biol 2008, 83:493-498.
19. Cho I., Blaser M.J. The human microbiome: at the interface of health and disease. Nat Rev Genet 2012, 13:260-270.
20. Alfonso-Loeches S., Urena-Peralta J.R., Morillo-Bargues M.J., et al. Role of mitochondria ROS generation in ethanol-induced NLRP3 inflammasome activation and cell death in astroglial cells. Front Cell Neurosci 2014, 8:216.
21. He Y., Franchi L., Nunez G. TLR agonists stimulate Nlrp3-dependent IL-1beta production independently of the purinergic P2X7 receptor in dendritic cells and in vivo. J Immunol 2013, 190:334-339.
22. Yang L., Lu X., Nossa C.W., et al. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology 2009, 137:588-597.
23. Macfarlane S., Furrie E., Macfarlane G.T., et al. Microbial colonization of the upper gastrointestinal tract in patients with Barrett's esophagus. Clin Infect Dis 2007, 45:29-38.
24. Amir I., Konikoff F.M., Oppenheim M., et al. Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors. Environ Microbiol 2014, 16:2905-2914.
25. Verbeek R.E., Siersema P.D., Ten Kate F.J., et al. Toll-like receptor 4 activation in Barrett's esophagus results in a strong increase in COX-2 expression. J Gastroenterol 2014, 49:1121-1134.
26. Cheng E., Zhang X., Huo X., et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut 2013, 62:824-832.
27. Jaiswal K.R., Morales C.P., Feagins L.A., et al. Characterization of telomerase-immortalized, non-neoplastic, human Barrett's cell line (BAR-T). Dis Esophagus 2007, 20:256-264.
28. Zhang X., Yu C., Wilson K., et al. Malignant transformation of non-neoplastic Barrett's epithelial cells through well-defined genetic manipulations. PLoS One 2010, 5:e13093.
29. Zhang H.Y., Zhang X., Chen X., et al. Differences in activity and phosphorylation of MAPK enzymes in esophageal squamous cells of GERD patients with and without Barrett's esophagus. Am J Physiol Gastrointest Liver Physiol 2008, 295:G470-G478.
30. Huo X., Zhang H.Y., Zhang X.I., et al. Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett's esophagus. Gastroenterology 2010, 139:194-203.e1.
31. Hilbi H., Chen Y., Thirumalai K., et al. The interleukin 1beta-converting enzyme, caspase 1, is activated during Shigella flexneri-induced apoptosis in human monocyte-derived macrophages. Infect Immun 1997, 65:5165-5170.
32. Yu C., Huo X., Agoston A.T., et al. Mitochondrial STAT3 contributes to transformation of Barrett's epithelial cells that express oncogenic Ras in a p53-independent fashion. Am J Physiol Gastrointest Liver Physiol 2015, 309:G146-G161.
33. Miao E.A., Rajan J.V., Aderem A. Caspase-1-induced pyroptotic cell death. Immunol Rev 2011, 243:206-214.
34. Abreu M.T., Peek R.M. Gastrointestinal malignancy and the microbiome. Gastroenterology 2014, 146:1534-1546.e3.
35. Zhou R., Yazdi A.S., Menu P., et al. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.
36. Plottel C.S., Blaser M.J. Microbiome and malignancy. Cell Host Microbe 2011, 10:324-335.
37. Tye H., Jenkins B.J. Tying the knot between cytokine and toll-like receptor signaling in gastrointestinal tract cancers. Cancer Sci 2013, 104:1139-1145.
38. Chen G.Y., Nunez G. Inflammasomes in intestinal inflammation and cancer. Gastroenterology 2011, 141:1986-1999.
39. Hagar J.A., Powell D.A., Aachoui Y., et al. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science 2013, 341:1250-1253.
40. Tschopp J., Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?. Nat Rev Immunol 2010, 10:210-215.
41. Wang X., Wang S., Hu C., et al. A new pharmacological effect of levornidazole: inhibition of NLRP3 inflammasome activation. Biochem Pharmacol 2015, 97:178-188.